Virtual Library

Start Your Search

Agata Raniszewska

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      192P - Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis (ID 444)

      12:30 - 13:00  |  Presenting Author(s): Agata Raniszewska

      • Abstract
      • Slides


      An immunotherapy was found to be effective in achieving long-term survival in some lung cancer patients and has emerged to searching for new immune biomarkers. It is suggested that lung cancer stem cells (LCSCs) are responsible for tumor initiation, maintenance and its metastatic potential. In our previous studies, we confirmed the presence of PD-L1 positive LCSCs (EPCAM+/CD133+) in metastatic lymph nodes (LNs). The aim of this study was to assess the presence of LCSCs in LNs aspirates using extended LCSCs markers and compare it with clinical data of patients.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      LCSCs were analyzed in LNs aspirates obtained during EBUS TBNA procedure. Flow cytometry with anti-CD44, anti-CXCR4 antibodies was applied to identify LCSCs. Additionally anti-PD-L1 was applied and geometric mean fluorescence (GMF) intensity of PD-L1 on LCSCs was measured.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      20 patients with confirmed non small cell lung cancer were enrolled. The highest proportion of PD-L1+ LCSCs was found in patients with metastatic disease; median values (p25-75)- 4,76% (1,51-7,65%) versus non metastatic- 0.01% (0-0,13%), p < 0.05. Higher percentage of PD-L1 positive LCSCs was found in patients with EGFR mutations and ALK rearrangements than in those without oncogenic addiction, p < 0.05. We observed significant correlation between proportion of PD-L1+ LCSCs and pack years smoked (r = 0.76, p < 0.05) and between expression (GMF) of PD-L1 and pack years smoked (r = 0.67, p < 0.05).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      We confirmed the significance of LCSCs in tumor growth and aggressiveness. LCSCs may serve as a potential strategy to enhance cancer immunotherapy efficacy. The development of predictive biomarkers is needed to optimize patient benefit and guide combination approaches.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.